Telix Pharmaceuticals Limited
TLX
$10.68
-$0.06-0.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -121.26% | -93.08% | -64.37% | -5.02% | 736.11% |
| Total Depreciation and Amortization | 297.38% | 261.20% | 184.99% | 123.58% | 29.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.93% | 17.15% | 171.93% | 222.94% | 5.65% |
| Change in Net Operating Assets | -5.12% | -27.48% | -78.70% | -78.70% | -78.70% |
| Cash from Operations | -163.03% | -91.45% | -22.81% | 105.50% | 96.07% |
| Capital Expenditure | -182.51% | -138.45% | -76.32% | -63.33% | -46.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -887.41% | -1,070.80% | -1,326.96% | -14,052.77% | -2,278.24% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.55% | -27.79% | -208.85% | -349.12% | -481.04% |
| Cash from Investing | -230.16% | -357.78% | -601.50% | -888.12% | -424.01% |
| Total Debt Issued | -99.88% | -1.53% | 8,087.43% | 8,053.82% | 7,685.76% |
| Total Debt Repaid | -193.70% | -223.11% | -169.37% | -172.63% | -18.96% |
| Issuance of Common Stock | 152.44% | -9.18% | -71.68% | -82.52% | -87.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 16.22% | -933.08% | -177.10% | -- |
| Cash from Financing | -100.89% | -3.21% | 7,753.72% | 8,716.51% | 5,866.89% |
| Foreign Exchange rate Adjustments | 555.51% | 1,240.05% | 675.77% | -66.66% | -283.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -183.81% | -149.09% | 1,363.57% | 13,831.48% | 6,364.38% |